Register for our free email digests:
Latest From NeurAxon Inc.
H.I.G. Capital, a global private equity firm with more than $8.5 billion under management, has closed its second life sciences-focused venture fund - H.I.G. BioVentures II – at $268 million, exceeding its $250 million target. Like its first life sciences fund, HIG BioVentures, the new fund will invest in North American companies across a broad range of sectors and development stages, with a focus on pharmaceuticals, medical devices, and diagnostics.
Cambridge-based biotech Bicycle Therapeutics has appointed Andy Sandham as non-executive chairman. Mr Sandham held previous roles at Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceutials, and continues to serve as chairman and CEO of Kymab and non-executive director of NeurAxon and PBL.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- NeurAxon Inc.
- Senior Management
- John S Andrews, PhD, Pres. & CSO
- Contact Info
Phone: (416) 673-6697
16-1375 Southdown Rd.
Mississauga, ON L5J 2Z1
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.